Postoperative cognitive dysfunction following major cancer surgery: a new approach to understanding cancer-associated cognitive decline

Active Grant Awarded

Award ID
R01CA311035
Recipient
Awarding agency
Obligated
$726,563

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 5% complete
Place of performance
Tampa, FL 33612, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. $726,563 in obligated funds on August 26, 2026, under Grant R01CA311035 in the Cancer Treatment Research program (CFDA 93.395). The award funds a study of postoperative cognitive dysfunction in older adults undergoing cystectomy for muscle-invasive bladder cancer, with or without neoadjuvant or adjuvant therapy, to determine how this dysfunction may contribute to cancer-associated cognitive decline. The study will recruit 200 patients aged 65 or older. Patients are assessed at recruitment, after neoadjuvant therapy where relevant, and at 1, 6, and 12 months after surgery, using frailty measures, a neuropsychological test battery, and patient-reported outcomes. Postsurgical delirium is assessed daily during inpatient recovery. Blood samples are collected within 24 hours of surgery and at each timepoint to assess inflammation, accelerated cellular aging, and neuronal injury. Stated aims include evaluating the incidence, severity, and chronicity of postoperative cognitive dysfunction and identifying its risk factors. The period of performance runs from the August 26, 2026 award date to an ultimate completion date of August 31, 2031. Place of performance is Tampa, FL 33612.

Description

Abstract
Postoperative cognitive dysfunction (POCD) is common in older adults, affecting up to 53% of surgical patients at hospital discharge and up 33% 3-6 months later. POCD is characterized by declines in attention, information processing, and memory, often accompanied by changes in mood and personality. Despite the fact that approximately 60% of cancer patients are treated with surgery, and cancer-associated cognitive decline (CACD) is well-documented, there is no research to our knowledge regarding how POCD may contribute to CACD. The current study will evaluate the prevalence, chronicity, risk factors, and biobehavioral mechanisms of POCD in older adults who undergo major cancer surgery. Specifically, we will recruit 200 patients aged 65 or older who are scheduled to undergo cystectomy with or without neoadjuvant or adjuvant therapy for muscle-invasive bladder cancer (MIBC). Patients will be assessed at recruitment; after neoadjuvant therapy (if relevant); and 1, 6, and 12 months after surgery. Assessments will consist of measures of frailty, a neuropsychological test battery, and patient-reported outcomes (PROS). Postsurgical delirium will be assessed daily during patients' inpatient recovery. A blood sample will be collected from patient participants within 24 hours of surgery and at each timepoint to assess putative acute and longitudinal biological mechanisms (i.e., inflammation, accelerated cellular aging, neuronal injury). Data will be used to address the following aims: 1) to evaluate the incidence, severity, and chronicity of POCD in older adults undergoing cystectomy with or without neoadjuvant or adjuvant chemotherapy for muscle invasive bladder cancer; 2) to identify risk factors for POCD in older adults undergoing cystectomy with or without neoadjuvant or adjuvant chemotherapy for muscle invasive bladder cancer; 3) to explore putative biological mechanisms of POCD in older adults with cancer, and 4) to explore associations of POCD with quality of life, healthcare utilization, and costs. This study will answer an important, unknown clinical question: what is the impact of major surgery on cognition in older cancer patients? Findings have the potential to improve patient and family education and informed consent for treatment. Findings may also point to new, evidence-based interventions to prevent or ameliorate cognitive decline in older adults with cancer (e.g., changes to anesthesia regimens, presurgical cognitive prehabilitation).

Quick answers

Who received award R01CA311035?

R01CA311035 was awarded to H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. by National Cancer Institute (National Institutes of Health) on August 26, 2026.

How much is award R01CA311035 worth?

$726,563 has been obligated on R01CA311035.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award